My point remains (and that I learned) is efficacy in rodent studies is more than just "in vitro" or quackery.

>layperson to worry about, either.

We're not talking about laypeople without money nor access to pursue. Adams had money, access, and desperation.

Society would love to put this to bed, but pharma typically avoids funding RCTs for out-of-patent/cheap drugs so we may never get the answer.